Advisor Group Holdings, Inc. Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Advisor Group Holdings, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$144.95 - $152.29 $122,192 - $128,380	-843 Reduced 23.85%	2,691 $407,000
Q2 2022 Aug 10, 2022	SELL	$83.14 - $145.99 $26,022 - $45,694	-313 Reduced 8.14%	3,534 $515,000
Q1 2022 May 04, 2022	BUY	$110.08 - $142.92 $34,675 - $45,019	315 Added 8.92%	3,847 $3.02 Million
Q3 2021 Nov 05, 2021	BUY	$98.85 - $138.91 $124,254 - $174,609	1,257 Added 55.25%	3,532 $491,000
Q2 2021 Aug 02, 2021	BUY	$65.78 - $105.02 $9,011 - $14,387	137 Added 6.41%	2,275 $221,000
Q1 2021 May 13, 2021	BUY	$64.07 - $91.75 $81,881 - $117,256	1,278 Added 148.6%	2,138 $146,000
Q4 2020 Feb 10, 2021	BUY	$65.07 - $98.24 $29,541 - $44,600	454 Added 111.82%	860 $74,000
Q3 2020 Nov 12, 2020	SELL	$59.04 - $77.95 $17,062 - $22,527	-289 Reduced 41.58%	406 $28,000
Q2 2020 Aug 14, 2020	BUY	$29.01 - $74.23 $3,075 - $7,868	106 Added 18.0%	695 $50,000
Q1 2020 May 18, 2020	BUY	$27.51 - $57.29 $16,203 - $33,743	589 New	589 $20,000

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.